Mabel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth 42.97%
- Profit Growth -2.02%
- Ebitda -91.84%
- Net Worth 11.46%
- Total Assets 55.00%
About Mabel Pharmaceuticals
Mabel Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 April 2016 (Eight years and nine months 5 days old ). Its registered office is in Haridwar, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Kamal Kishor, Naveen Pant, and Naresh Pant serve as directors at the Company.
Company Details
-
Location
Haridwar, Uttarakhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999UR2016PTC007023
-
Company No.
007023
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Apr 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Mabel Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Kishor
|
Director | 27-Apr-2016 | Current |
|
Naveen Pant
|
Director | 27-Apr-2016 | Current |
|
Naresh Pant
|
Director | 20-Nov-2023 | Current |
Financial Performance of Mabel Pharmaceuticals.
Mabel Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.97% increase. The company also saw a slight decrease in profitability, with a 2.02% decrease in profit. The company's net worth Soared by an impressive increase of 11.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mabel Pharmaceuticals?
In 2018, Mabel Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Nov 2017 | State Bank Of India | ₹0.50 M | Open |
How Many Employees Work at Mabel Pharmaceuticals?
Unlock and access historical data on people associated with Mabel Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mabel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mabel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
